Retatrutide 20mg

Description

Certificate of analysis — withheld, and why. The supplier certificate we hold for retatrutide is deliberately not published. The laboratory tested against an expected content of 10.00 mg and measured 23.01 mg. The purity figure — 99.82% by HPLC-UV — is not in question; the declared content is. Our supplier’s account is that a 20 mg vial was submitted for testing and the certificate was then applied to both fills, which would reconcile the figure, but that has not been documented. We would rather show nothing than publish a certificate we cannot stand behind, so it stays down, with the full reasoning at sentientbiogenix.com/coa/retatrutide-20mg. Retatrutide is the first compound we are sending for independent third-party testing in our own name, on a Sentient-labelled vial, and that certificate will be published here when it is issued. The vials in stock today came from an earlier supplier and will not be covered by it — that certificate will cover the batch which replaces them. Everything we do hold a certificate for is listed on our COA page.

Retatrutide is an investigational, long-acting peptide that activates GLP-1, GIP, and glucagon receptors, studied for its effects on appetite regulation, glucose homeostasis, energy expenditure, and multi-system metabolic pathways in obesity, diabetes, and liver-fat research models.

*Sentient Biogenix products are intended solely for non‑clinical laboratory research. It is not approved by Health Canada, the FDA, or any other regulatory authority, and is not for human or animal consumption, nor for diagnostic, therapeutic, or clinical use.